GE Health care has licensed to Ascendance Biotechnology rights to produce, market, and sell the GE Healthcare Cytiva ® brand of human stem cell-derived cardiomyocytes employed for evaluating potential cardiotoxicity, Ascendance said today.

The value of the license agreement was not disclosed.

Cytiva joins Ascendance’ s first stem cell-derived item, VascuNet TM , designed to analyze the capability associated with cancer drug candidates to inhibit the formation associated with blood vessels, and which is also being evaluated as a tool pertaining to understanding the toxicologic effects of drug candidates on endothelial cellular material.

Ascendance said the addition to its products of the Cytiva cardiomyocytes is expected to further solidify the particular company’ s leadership position in the within vitro toxicology testing market, which based on Market and Markets is projected to reach more than $17 billion by 2018.

“ The ongoing expansion of the company’ s offerings beyond liver cell-based products to include both products and services based on multiple cell varieties is expected to augment revenue growth for Ascendance, that is currently driven primarily by our line of HepatoPac ® and HepatoMune ® micro-patterned co-culture products, ” Ascendance President Jeffrey Janus said in a statement.

Ascendance’ h HepatoPac ® and HepatoMune ® products, which contain hepatocytes, are designed with regard to in vitro metabolite evaluation, as well as toxicology and efficacy screening.

Launched as a successor to Hepregen and the ESI BIO Department of BioTime, Ascendance develops its own proprietary intellectual home and licenses technology from MIT, Colorado State University or college, BioTime, and two wholly owned subsidiaries of BioTime, ES Cell International and ReCyte Therapeutics.